An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of Octaplas in the Management of Pediatric Patients Who Require Replacement of Multiple Coagulation Factors.

Trial Profile

An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of Octaplas in the Management of Pediatric Patients Who Require Replacement of Multiple Coagulation Factors.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Plasma (Primary)
  • Indications Blood coagulation disorders
  • Focus Adverse reactions
  • Sponsors Octapharma
  • Most Recent Events

    • 13 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 28 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
    • 28 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top